The ISCTH Global Peace and Transformation Summit with a powerful message from Maitreya Dadashreeji - #IamPeace
Geneva, Switzerland
On the 28th of June 2024, the International Spiritual Council for Transforming Humanity (ISCTH) hosted the first Global Peace and Transformation Summit in Geneva, Siwtzerland. More than 100 action-driven leaders and influential speakers from around the globe gathered to open an honest dialogue on how to foster permanent world peace.
History shows that when faced with chaos, people often resort to conflict, but this hasn't solved our problems. Instead, we propose a different way: the path of peace. Ask yourself, "What are you seeking?" If you are unhappy, disturbed, you have some self-reflecting to do. The chaos we see around us is a mirror of our own inner state. Through ISCTH and the growing community, we can pave the way for the great transformation. According to the powerful keynote message from Maitreya Dadashreeji, for a collective approach, as a community, there are three steps which we can build upon and implement together.
- Right Values: Integrate compassion, empathy, and love into daily life, education, and community for peaceful relationships.
- Right Leadership: Prioritize compassionate, community-focused leaders for a harmonious world.
- Right Purpose: Focus on creating happy, supportive communities and guiding individuals towards positive spiritual growth.
If you feel disturbed, the antidote is peace. When you acknowledge "I am disturbed," it tends to intensify. Instead, embrace the thought "I am peace," and everything begins to settle internally. Make "I am peace" a daily affirmation, as your true nature is peace. Spend 10 minutes each day connecting with this truth. By doing so, you align your emotions and thoughts with peace. This movement, both individually and collectively, will help lay the foundation of a more harmonious world. From inner peace to world peace. #IamPeace
Contacts
Contact: media@iscth.org
+41775326570
Website: www.iscth.org
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
Dr. Stefanie Kesting appointed as CEO of Thyssengas7.1.2026 14:06:26 CET | Press release
Dortmund, 06.01.2026 As of January 1, 2026, Dr. Stefanie Kesting has been appointed as the new Chief Executive Officer (CEO) of Thyssengas GmbH. She succeeds Dr. Thomas Gößmann, who will retire at the end of February 2026 after nearly nine years at the helm of the company. The leadership transition was announced in autumn 2025.
30 Years of European Spas: Nature, Natural Remedies and Climate Health as Europe’s Unique Strength7.1.2026 08:59:31 CET | Press release
To mark its 30th anniversary, the European Spas Association (ESPA) has released a special commemorative publication highlighting the strategic role of Europe’s medical spas and climate-health resorts in an era defined by prevention, longevity and sustainable wellbeing.
Forum for a self-reliant and self-determined Europe - the "Sovereign Europe Forum"23.12.2025 08:40:47 CET | Press release
Entrepreneurs, top managers and leaders from United Europe e.V. and European Forum Alpbach (EFA) are founding the Sovereign Europe Forum i.G.
Digital Subsidiary of Austrian State Printing Company Wins Infrastructure Tender for German EU Digital Identity Wallet22.12.2025 15:12:30 CET | Press release
youniqx Identity, a digital subsidiary of the Austrian State Printing Company (OSD), has won a Europe-wide tender, together with partner companies, for the infrastructure of the German EU Digital Identity Wallet (EUDI-Wallet). EU member states are required by EU regulations to provide a national version of an EU-wide valid EUDI-Wallet by the end of 2026. Citizens will be able to use the EUDI-Wallet to prove their personal identity throughout the EU
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom